Health Bulletin 9/February/2022

Here are Top health stories of the day

Coronavirus Omicron variant India : 1,114 new cases in Delhi, 447 in Mumbai

OmiSure RT-PCR test detects sub-lineages of Omicron : Tata Medical and Diagnostics

Tata Medical and Diagnostics on Tuesday said its OmiSure RT-PCR(Reverse Transcriptase Polymerase Chain Reaction) test has been upgraded to detect the new BA.2 sub-lineages of Omicron. In an evaluation carried out by ICMR and the Virus Research & Diagnostics Laboratory, Kasturba Hospital for Infectious Diseases, Mumbai, the upgraded OmiSure successfully detected BA.1, BA.1.1, and BA.2 sub-lineages of Omicron, the company said in a statement.

With this, the OmiSure RT-PCR test kit is now capable of detecting all the sub-lineages of Omicron prolific in India at present, it added.

For more information, check out the full story on the link below:

OmiSure RT-PCR test detects sub-lineages of Omicron : Tata Medical And Diagnostics

11,629 MD, MS, PG Diploma, DNB seats up for grabs in MCC NEET PG counselling round 2, check out seat matrix

There are a total of 11,629 MD, MS, PG Diploma and DNB seats available for NEET PG Counselling candidates participating in the Round 2 session being conducted by the Medical Counselling Committee, MCC under DGHS.

The confirmation of this aggregate comes from the recently released Round 2 seat matrix on the official website of the Medical Counselling Committee (MCC) indicating the number of MD, MS DNB and PG Diploma seats being offered for the second round of NEET PG Counselling as per the categories available in medical institutes across the country.

For more information, check out the full story on the link below:

11,629 MD, MS, PG Diploma, DNB seats up for grabs in MCC NEET PG Counselling Round 2, Check out seat matrix

COVID-19: Glenmark Launches FabiSpray In India

Drug maker Glenmark Pharmaceuticals Limited and Canadian pharmaceutical company SaNOtize Research & Development Corp. today announced launch of its Nitric Oxide Nasal Spray under the brand name FabiSpray in India; for the treatment of adult patients with COVID-19 who have high risk of progression of the disease.

Glenmark earlier received manufacturing and marketing approval from the Drugs Controller General of India (DCGI) for NONS as part of the accelerated approval process.

For more information, check out the full story on the link below: 

COVID-19: Glenmark launches FabiSpray in India